These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients. Chang YT; Guo CY; Tsai MS; Cheng YY; Lin MT; Chen CH; Shen D; Wang JR; Sung JM Vaccine; 2012 Jul; 30(33):5009-18. PubMed ID: 22658967 [TBL] [Abstract][Full Text] [Related]
27. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995 [TBL] [Abstract][Full Text] [Related]
28. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422 [TBL] [Abstract][Full Text] [Related]
29. Assessment of CD8 Evans TG; Castellino F; Kowalik Dobczyk M; Tucker G; Walley AM; Van Leuven K; Klein J; Rutkowski K; Ellis C; Eagling-Vose E; Treanor J; van Baalen C; Filkov E; Laurent C; Thacker J; Asher J; Donabedian A Lancet Microbe; 2024 Jul; 5(7):645-654. PubMed ID: 38729196 [TBL] [Abstract][Full Text] [Related]
30. A randomized clinical trial assessing immunogenicity and safety of a double dose of virosomal-adjuvanted influenza vaccine administered to unprimed children aged 6-35 months. Esposito S; Marchisio P; Ansaldi F; Bianchini S; Pacei M; Baggi E; Trabattoni D; Icardi G; Principi N Vaccine; 2010 Aug; 28(38):6137-44. PubMed ID: 20670909 [TBL] [Abstract][Full Text] [Related]
31. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Treanor J; Nolan C; O'Brien D; Burt D; Lowell G; Linden J; Fries L Vaccine; 2006 Jan; 24(3):254-62. PubMed ID: 16129526 [TBL] [Abstract][Full Text] [Related]
32. Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial. Boffito M; Fox J; Bowman C; Fisher M; Orkin C; Wilkins E; Jackson A; Pleguezuelos O; Robinson S; Stoloff GA; Caparrós-Wanderley W Vaccine; 2013 Nov; 31(48):5680-6. PubMed ID: 24120550 [TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Sirima SB; Nébié I; Ouédraogo A; Tiono AB; Konaté AT; Gansané A; Dermé AI; Diarra A; Ouédraogo A; Soulama I; Cuzzin-Ouattara N; Cousens S; Leroy O Vaccine; 2007 Mar; 25(14):2723-32. PubMed ID: 17280744 [TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Chu DW; Hwang SJ; Lim FS; Oh HM; Thongcharoen P; Yang PC; Bock HL; Dramé M; Gillard P; Hutagalung Y; Tang H; Teoh YL; Ballou RW; Vaccine; 2009 Dec; 27(52):7428-35. PubMed ID: 19683087 [TBL] [Abstract][Full Text] [Related]
35. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. Bernstein DI; Edwards KM; Dekker CL; Belshe R; Talbot HK; Graham IL; Noah DL; He F; Hill H J Infect Dis; 2008 Mar; 197(5):667-75. PubMed ID: 18260764 [TBL] [Abstract][Full Text] [Related]
36. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age. Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661 [TBL] [Abstract][Full Text] [Related]
38. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination. Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415 [TBL] [Abstract][Full Text] [Related]
39. ISCOM-matrix-based equine influenza (EIV) vaccine stimulates cell-mediated immunity in the horse. Paillot R; Prowse L Vet Immunol Immunopathol; 2012 Jan; 145(1-2):516-21. PubMed ID: 22178272 [TBL] [Abstract][Full Text] [Related]
40. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]